APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Lung Tumor Embolization

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Lung Tumor Embolization Market Outlook and Growth Opportunities 2026

4 July 2026198 pages

Choose your research edition.

Industry ResearchLung Tumor Embolization Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Lung Tumor Embolization Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Lung Tumor Embolization Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lung Tumor Embolization Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Lung Tumor Embolization Market Analysis and Forecast 2026-2032175 pages · $4,950 USD

Market perspective

The global Lung Tumor Embolization market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Lung Tumor Embolization is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lung Tumor Embolization is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lung Tumor Embolization is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Lung Tumor Embolization market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Lung Tumor Embolization market include Tendfo, Medtronic, Olympus, Penumbra and Inari Medical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Lung Tumor Embolization market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lung Tumor Embolization and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lung Tumor Embolization revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Lung Tumor Embolization market.

Lung Tumor Embolization Segment by Company

Tendfo

Medtronic

Olympus

Penumbra

Inari Medical

Lung Tumor Embolization Segment by Type

Transarterial chemoembolization (TACE)

Transarterial Radioembolization (TARE)

Others

Lung Tumor Embolization Segment by Application

Hospitals

Ambulatory Surgical Centers

Lung Tumor Embolization Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Lung Tumor Embolization status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Lung Tumor Embolization key companies, revenue, market share, and recent developments.

3. To split the Lung Tumor Embolization breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Lung Tumor Embolization market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lung Tumor Embolization significant trends, drivers, influence factors in global and regions.

6. To analyze Lung Tumor Embolization competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Tumor Embolization market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lung Tumor Embolization and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Tumor Embolization.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lung Tumor Embolization industry.

Chapter 3: Detailed analysis of Lung Tumor Embolization company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Lung Tumor Embolization in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Lung Tumor Embolization in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lung Tumor Embolization Industry Trends Table 2. Lung Tumor Embolization Industry Drivers Table 3. Lung Tumor Embolization Industry Opportunities and Challenges Table 4. Lung Tumor Embolization Industry Restraints Table 5. Global Lung Tumor Embolization Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lung Tumor Embolization Revenue Share by Company (2021-2026) Table 7. Global Lung Tumor Embolization Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Lung Tumor Embolization Key Company Manufacturing Base & Headquarters Table 9. Global Lung Tumor Embolization Company, Product Type & Application Table 10. Global Lung Tumor Embolization Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Lung Tumor Embolization by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Transarterial chemoembolization (TACE) Table 15. Significant Companies of Transarterial Radioembolization (TARE) Table 16. Significant Companies of Others Table 17. Global Lung Tumor Embolization Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Lung Tumor Embolization Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Lung Tumor Embolization Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Lung Tumor Embolization Sales Value Share by Type (2021-2026) Table 21. Global Lung Tumor Embolization Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Ambulatory Surgical Centers Table 24. Global Lung Tumor Embolization Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Lung Tumor Embolization Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Lung Tumor Embolization Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Lung Tumor Embolization Sales Value Share by Application (2021-2026) Table 28. Global Lung Tumor Embolization Sales Value Share by Application (2027-2032) Table 29. Global Lung Tumor Embolization Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Lung Tumor Embolization Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Lung Tumor Embolization Sales Value Share by Region (2021-2026) Table 32. Global Lung Tumor Embolization Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Lung Tumor Embolization Sales Value Share by Region (2027-2032) Table 34. Global Lung Tumor Embolization Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Lung Tumor Embolization Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Lung Tumor Embolization Sales Value Market Share by Country (2021-2026) Table 37. Global Lung Tumor Embolization Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Lung Tumor Embolization Sales Value Market Share by Country (2027-2032) Table 39. Tendfo Company Information Table 40. Tendfo Business Overview Table 41. Tendfo Lung Tumor Embolization Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Tendfo Lung Tumor Embolization Product Portfolio Table 43. Tendfo Recent Development Table 44. Medtronic Company Information Table 45. Medtronic Business Overview Table 46. Medtronic Lung Tumor Embolization Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Medtronic Lung Tumor Embolization Product Portfolio Table 48. Medtronic Recent Development Table 49. Olympus Company Information Table 50. Olympus Business Overview Table 51. Olympus Lung Tumor Embolization Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Olympus Lung Tumor Embolization Product Portfolio Table 53. Olympus Recent Development Table 54. Penumbra Company Information Table 55. Penumbra Business Overview Table 56. Penumbra Lung Tumor Embolization Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Penumbra Lung Tumor Embolization Product Portfolio Table 58. Penumbra Recent Development Table 59. Inari Medical Company Information Table 60. Inari Medical Business Overview Table 61. Inari Medical Lung Tumor Embolization Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Inari Medical Lung Tumor Embolization Product Portfolio Table 63. Inari Medical Recent Development Table 64. Research Programs/Design for This Report Table 65. Authors List of This Report Table 66. Secondary Sources Table 67. Primary Sources List of Figures Figure 1. Lung Tumor Embolization Product Image Figure 2. Global Lung Tumor Embolization Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lung Tumor Embolization Market Size (2021-2032) & (US$ Million) Figure 4. Global Lung Tumor Embolization Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Transarterial chemoembolization (TACE) Image Figure 8. Transarterial Radioembolization (TARE) Image Figure 9. Others Image Figure 10. Global Lung Tumor Embolization Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Lung Tumor Embolization Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Lung Tumor Embolization Sales Value Share by Type (2021-2032) Figure 13. Hospitals Image Figure 14. Ambulatory Surgical Centers Image Figure 15. Global Lung Tumor Embolization Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Lung Tumor Embolization Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Lung Tumor Embolization Sales Value Share by Application (2021-2032) Figure 18. Global Lung Tumor Embolization Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Lung Tumor Embolization Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Lung Tumor Embolization Sales Value (2021-2032) & (US$ Million) Figure 21. North America Lung Tumor Embolization Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Lung Tumor Embolization Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Lung Tumor Embolization Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Lung Tumor Embolization Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Lung Tumor Embolization Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Lung Tumor Embolization Sales Value (2021-2032) & (US$ Million) Figure 27. South America Lung Tumor Embolization Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Lung Tumor Embolization Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Lung Tumor Embolization Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Lung Tumor Embolization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Transarterial chemoembolization (TACE)
  • Transarterial Radioembolization (TARE)
  • Others
Applications
  • Hospitals
  • Ambulatory Surgical Centers
Companies covered
  • Tendfo
  • Medtronic
  • Olympus
  • Penumbra
  • Inari Medical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lung Tumor Embolization Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lung Tumor Embolization Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Lung Tumor Embolization Market Dynamics
  1. 2.1 Lung Tumor Embolization Industry Trends
  2. 2.2 Lung Tumor Embolization Industry Drivers
  3. 2.3 Lung Tumor Embolization Industry Opportunities and Challenges
  4. 2.4 Lung Tumor Embolization Industry Restraints
3 Lung Tumor Embolization Market by Company
  1. 3.1 Global Lung Tumor Embolization Company Revenue Ranking in 2025
  2. 3.2 Global Lung Tumor Embolization Revenue by Company (2021-2026)
  3. 3.3 Global Lung Tumor Embolization Company Ranking (2024-2026)
  4. 3.4 Global Lung Tumor Embolization Company Manufacturing Base and Headquarters
  5. 3.5 Global Lung Tumor Embolization Company Product Type and Application
  6. 3.6 Global Lung Tumor Embolization Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Lung Tumor Embolization Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Lung Tumor Embolization Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Lung Tumor Embolization Market by Type
  1. 4.1 Lung Tumor Embolization Type Introduction
  2. 4.1.1 Transarterial chemoembolization (TACE)
  3. 4.1.2 Transarterial Radioembolization (TARE)
  4. 4.1.3 Others
  5. 4.2 Global Lung Tumor Embolization Sales Value by Type
  6. 4.2.1 Global Lung Tumor Embolization Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Lung Tumor Embolization Sales Value by Type (2021-2032)
  8. 4.2.3 Global Lung Tumor Embolization Sales Value Share by Type (2021-2032)
5 Lung Tumor Embolization Market by Application
  1. 5.1 Lung Tumor Embolization Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Ambulatory Surgical Centers
  4. 5.2 Global Lung Tumor Embolization Sales Value by Application
  5. 5.2.1 Global Lung Tumor Embolization Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Lung Tumor Embolization Sales Value by Application (2021-2032)
  7. 5.2.3 Global Lung Tumor Embolization Sales Value Share by Application (2021-2032)
6 Lung Tumor Embolization Regional Value Analysis
  1. 6.1 Global Lung Tumor Embolization Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lung Tumor Embolization Sales Value by Region (2021-2032)
  3. 6.2.1 Global Lung Tumor Embolization Sales Value by Region: 2021-2026
  4. 6.2.2 Global Lung Tumor Embolization Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lung Tumor Embolization Sales Value (2021-2032)
  7. 6.3.2 North America Lung Tumor Embolization Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Lung Tumor Embolization Sales Value (2021-2032)
  10. 6.4.2 Europe Lung Tumor Embolization Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Lung Tumor Embolization Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Lung Tumor Embolization Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Lung Tumor Embolization Sales Value (2021-2032)
  16. 6.6.2 South America Lung Tumor Embolization Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Lung Tumor Embolization Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Lung Tumor Embolization Sales Value Share by Country, 2025 VS 2032
7 Lung Tumor Embolization Country-level Value Analysis
  1. 7.1 Global Lung Tumor Embolization Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lung Tumor Embolization Sales Value by Country (2021-2032)
  3. 7.2.1 Global Lung Tumor Embolization Sales Value by Country (2021-2026)
  4. 7.2.2 Global Lung Tumor Embolization Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Lung Tumor Embolization Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Lung Tumor Embolization Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Lung Tumor Embolization Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Tendfo
  2. 8.1.1 Tendfo Company Information
  3. 8.1.2 Tendfo Business Overview
  4. 8.1.3 Tendfo Lung Tumor Embolization Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Tendfo Lung Tumor Embolization Product Portfolio
  6. 8.1.5 Tendfo Recent Developments
  7. 8.2 Medtronic
  8. 8.2.1 Medtronic Company Information
  9. 8.2.2 Medtronic Business Overview
  10. 8.2.3 Medtronic Lung Tumor Embolization Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Medtronic Lung Tumor Embolization Product Portfolio
  12. 8.2.5 Medtronic Recent Developments
  13. 8.3 Olympus
  14. 8.3.1 Olympus Company Information
  15. 8.3.2 Olympus Business Overview
  16. 8.3.3 Olympus Lung Tumor Embolization Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Olympus Lung Tumor Embolization Product Portfolio
  18. 8.3.5 Olympus Recent Developments
  19. 8.4 Penumbra
  20. 8.4.1 Penumbra Company Information
  21. 8.4.2 Penumbra Business Overview
  22. 8.4.3 Penumbra Lung Tumor Embolization Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Penumbra Lung Tumor Embolization Product Portfolio
  24. 8.4.5 Penumbra Recent Developments
  25. 8.5 Inari Medical
  26. 8.5.1 Inari Medical Company Information
  27. 8.5.2 Inari Medical Business Overview
  28. 8.5.3 Inari Medical Lung Tumor Embolization Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Inari Medical Lung Tumor Embolization Product Portfolio
  30. 8.5.5 Inari Medical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst